Evidence map›Paper›PMID 36287804›Full record

ArticleTomography (Ann Arbor, Mich.)2022

Prostate Cancer Biochemical Recurrence Resulted Negative on [

Riccardo Laudicella, Flavia La Torre, Valerio Davì, Ludovica Crocè, Demetrio Aricò, Giuseppe Leonardi, Simona Russo, Fabio Minutoli, Irene A Burger, Sergio Baldari

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Tomography (Ann Arbor, Mich.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.European journal of nuclear medicine and molecular imaging · 2025
    Review
  3. Dual targeting PET tracer [Theranostics · 2025
    Article
  4. Article
  5. mCRPC progression of disease after [Urology case reports · 2024
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Riccardo LaudicellaNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.ORCID 0000-0002-2842-0301
Flavia La TorreNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.
Valerio DavìNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.ORCID 0000-0002-0532-4253
Ludovica CrocèNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.
Demetrio AricòDepartment of Nuclear Medicine, Humanitas Oncological Centre of Catania, 95125 Catania, Italy.ORCID 0000-0002-5798-9943
Giuseppe LeonardiNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.
Simona RussoNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.
Fabio MinutoliNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.
Irene A BurgerDepartment of Nuclear Medicine, University Hospital Zürich, University of Zürich, 8091 Zürich, Switzerland.ORCID 0000-0001-8029-8692
Sergio BaldariNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging technique by the European Association of Urology (EAU) guidelines is prostate-specific membrane antigen (PSMA) positron emission tomography/computer tomography (PET/CT). Indeed, the increased detection rate of PSMA PET/CT for early BCR has led to a fast and wide acceptance of this novel technology. However, PCa is a very heterogeneous disease, not always easily assessable with the highly specific PSMA PET with around 10% of cases occuring without PSMA expression. In this paper, we present the case of a patient with PCa BCR that resulted negative on [

Indexed as

Gallium RadioisotopesProstatic NeoplasmsCholineComputersHumansMalePositron-Emission TomographyPositron Emission Tomography Computed TomographyCholinefluorocholinefluoromethylcholineGallium Radioisotopesbiochemical recurrencecholinePETprostate cancerPSMA

Identifiers

PMID36287804
PMCPMC9609559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.